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A B S T R A C T
We report a case of infective endocarditis due to vancomycin-intermediate Staphylococcus aureus (VISA).
This was treatedwith a combination of intravenous linezolid and fusidic acid. Cure was achieved without
surgical intervention.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Ten years after the ﬁrst description of a Staphylococcus aureus
strain with reduced susceptibility to vancomycin (vancomycin-
intermediate S. aureus or VISA) in Japan,1 VISA have resulted in
many infections worldwide. Only a few cases of endocarditis
caused by VISA have been reported so far. Management of
endocarditis caused by VISA is often difﬁcult and the ideal therapy
for patients with endocarditis due to VISA is unknown.
We report a case of endocarditis caused by VISA demonstrating
the successful use of linezolid therapy for this condition.
2. Case report
A 57-year-old male with grade II gastric adenocarcinoma
diagnosed in March 2004 underwent a partial gastrectomy and
subsequent chemotherapy (5-ﬂuorouracil). Three weeks after the
ﬁrst cycle of chemotherapy he developed an intestinal obstruction
for which he underwent resection and anastomosis. His postoper-
ative course was complicated by ventilator-associated pneumonia
and bacteremia. Methicillin-resistant S. aureus (MRSA) was* Corresponding author. Tel.: +968 24 144935; fax: +968 24 141198.
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doi:10.1016/j.ijid.2009.07.023isolated from tracheal secretions and blood cultures. Methicillin
susceptibility testing was performed using the disk diffusion
method, E test for oxacillin, PBP2 test kit for the detection of PBP2
(by Oxoid, UK), and Phoenix Identiﬁcation and Susceptibility
System (Becton Dickinson, USA, Sparks, MD, USA).
The patient was placed in strict isolation and an epidemiologic
investigation was performed in accordance with the hospital
policy. The patient was started on intravenous vancomycin 15 mg/
kg every 12 h. No screened persons were colonized with MRSA.
Follow-up blood cultures (on vancomycin) for sterility on days
7 and 10 continued to grow MRSA despite adequate serum levels
(vancomycin levels: peak 30 mg/ml and trough 8 mg/ml).
In view of the persistence of bacteremia, a transthoracic
echocardiography was done. It showed vegetations on the mitral
valve (posterior leaﬂet; Figure 1).
A diagnosis of MRSA endocarditis was made. Gentamicin 1 mg/
kg every 8 h intravenously was then added for synergism, and
valve surgery was contemplated. The isolate was sent for
vancomycin susceptibility testing. Persistence of bacteremia was
attributed to the presence of endovascular infection (MRSA
endocarditis). During this period the patient remained clinically
well but continued to have a low grade fever.
Follow-up blood cultures on days 14 and 17 continued to grow
MRSA despite optimal vancomycin serum levels. These two
isolates (from days 14 and 17) and the previous three isolatesses. Published by Elsevier Ltd. All rights reserved.
Figure 2. 2D transthoracic echocardiogram (ﬁfth week of treatment with linezolid), long axis left parasternal view (a) and apical four-chamber view (b) with no evidence of
vegetations. Posterior mitral valve leaﬂet is freely mobile.
Figure 1. 2D transthoracic echocardiogram (secondweek on vancomycin, prior to therapywith linezolid), long axis left parasternal view (a) and apical four-chamber view (b)
demonstrating a well circumscribed vegetation measuring 2  1 cm, conﬁned to the posterior mitral valve leaﬂet and impinging on the left atrium.
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using the Etest and Phoenix Identiﬁcation and Susceptibility
System (Becton Dickinson). The minimum inhibitory concentra-
tion (MIC) to vancomycinwas 4mg/ml (intermediately susceptible
based on current deﬁnitions) for isolates from days 0, 7 and 10, and
8 mg/ml for isolates from days 14 and 17. (The test was repeated
twice using bothmethods). All isolates were uniformly resistant to
rifampin but susceptible to both linezolid and fusidic acid.
The isolatewas classiﬁed as VISAwith susceptibility to linezolid
and fusidic acid. The antibiotic regimen was the changed to
intravenous linezolid 600 mg every 12 h and fusidic acid 500 mg
every 8 h (on day 17 following onset of bacteremia). Vancomycin
was discontinued. The patient became afebrile less than 48 h after
starting linezolid therapy. In view of the stability of the patient’s
condition, valve surgery was delayed to see if the new regimen
could achieve sterility prior to surgery. Multiple surveillance blood
cultures performed during linezolid therapy all yielded no growth.
Follow-up echocardiography on day 14 of linezolid and fusidic acid
therapy conﬁrmed near resolution of the vegetation. Subsequent
echocardiography at ﬁve weeks of linezolid therapy conﬁrmed
total resolution of the vegetation (Figure 2).
A total of six weeks of intravenous linezolid was given (with
fusidic acid for the ﬁrst twoweeks). Linezolid-induced neutropenia
complicated the course of treatment but was managed with
granulocyte colony stimulating factor (GCSF).
Cure was achieved and the patient was discharged home.3. Discussion
We have described a case of bacteremia and endocarditis
caused by VISA. Failure to respond to prolonged (17 days)
therapy with vancomycin was demonstrated. However, the
combination of linezolid and fusidic acid resulted in a prompt
clinical response and subsequent cure, with complete resolution
of vegetations. This is the ﬁrst documented case of VISA
endocarditis in Oman.
The ﬁrst strain of VISA was described in Japan in 1997 by
Hiramatsu et al.1–3 Since then a number of VISA isolates have been
reported from different parts of the world.4 In the USA alone, 16
cases of VISA isolates has been reported so far.5 To our knowledge,
there have been no published reports on VISA isolates from Oman.
The Clinical and Laboratory Standards Institute’s (CLSI) early
deﬁnition of VISA was S. aureuswith a vancomycin MIC level of 8–
16 mg/ml.6 Based on this deﬁnition, the initial isolates (vancomy-
cin MIC of 4mg/ml) were not labeled as VISA and vancomycin was
continued,while subsequent isolates (vancomycinMIC of 8mg/ml)
were labeled as VISA, hence linezolid was initiated. Currently, the
CLSI deﬁnes VISA as S. aureus with a vancomycin MIC level of 4–
8mg/ml.7With this current deﬁnition, all isolates from this patient
were actually VISA.
Changes in cell physiology due to the accumulation ofmutations
have been implicated in the development of vancomycin resistance
in VISA. VISA clinical strains have thickened cell walls, which result
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through the cell wall peptidoglycan layers.8,9
VISA isolates are not detected by all susceptibility testing
methods, for example disk diffusionmethods fail to detect these.10
Methods that typically detect VISA are non-automated MIC
methods, including reference broth microdilution, agar dilution,
and the Etest using a 0.5 McFarland standard.10 In our case we
detected the VISA isolates using both the Etest and the automated
system with 100% agreement.
Several published reports of VISA infections suggest that VISA
strains appear to have developed from pre-existing MRSA strains
that infected the patients in the months before the VISA infection,
and prolonged exposure to vancomycin is among the known risk
factors for the development of VISA strains.11 In our patient, it is
not evident as towhy he developed a serious infectionwith VISA in
the absence of clear risk factors.
Treatment failure with vancomycin has been documented
when the vancomycin MIC of S. aureus is 4mg/ml.12 This case
further illustrates this concerning problem. When this happens
clinicians should look for alternatives to vancomycin.
Linezolid is the ﬁrst member of a new class of synthetic
antibacterial agents known as oxazolidinones. Its mechanism of
action is unique and it has potent activity against Gram-positive
bacteria, including multi-resistant strains e.g. VISA.13 The devel-
opment of resistance to linezolid has been infrequent and reported
in only few clinical isolates.14
At present, linezolid is not a standard therapy for endocarditis,
although guidelines published by the American Heart Association
consider it to be a reasonable alternative for cases of endocarditis
caused byMRSA ormulti-resistant enterococci.15 To date, there are
11 published cases of infective endocarditis caused by S. aureus
with reduced susceptibility to vancomycin treated with linezolid.
Seven of the 11 cases were reported to have satisfactory
responses.15 We are reporting the ﬁrst case of VISA endocarditis
in Oman. This case was successfully treated with a combination of
linezolid and fusidic acid.
4. Conclusions
Wehave documented a case of bacteremia and endocarditis due
to a VISA strain that did not respond to optimized, prolongedtreatment with vancomycin. In contrast, intravenous linezolid
resulted in a prompt clinical response and cure. This case
emphasizes the clinical importance of S. aureus strains with
decreased susceptibility to vancomycin.
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